Raltegravir Potassium
Treatment of human immunodeficiency virus (HIV-1) infection in treatment naïve patients in combination with other antiretroviral agents, with evidence of HIV replication (viral load >10,000 copies/mL) and/or CD4 cell counts <500 per cubic millimetre.
Access path
- Mar 2010Recommended · restricted
Comparator changed: efavirenz → efavirenz (with nevirapine, atazanavir…
- Mar 2010Recommended · restricted
Comparator changed: efavirenz → efavirenz (with nevirapine, atazanavir…
- PBS listing · Restricted
Cost-effectiveness
ICER range cited: base case $10,000–$50,000 per QALY; $50,000–$100,000 per QALY when lower 95% CI of treatment effect is used. However, PBAC recommended on cost-minimisation basis, not cost-utility.
Hence, the uncertainty in the model was reflected in the large variation of the ICER from the base case of $10,000 to $50,000 per year per quality adjusted life year (QALY) to $50,000 to $100,000 per QALY when the lower 95 % confidence limit of treatment effect is used. PBAC · 2010
Decision context
PopulationTreatment naïve patients with HIV-1 infection in combination with optimised background antiretroviral therapy, with evidence of HIV replication (viral load >10,000 copies/mL) and/or CD4 cell counts <500 per cubic millimetre.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2010 | Recommended · restricted | efavirenz | $10k–100k | RCT · HIV RNA <50 |
| Mar 2010 | Recommended · restricted | efavirenz (with nevirapine, atazanavir, lopinavir/ritonavir, and darunavir in indirect comparison) | $10k–100k | RCT · HIV RNA <50 copies/mL |